Serum uric acid is independently associated with hypertension in patients with polymyositis and dermatomyositis

• Published in: The journal of clinical hypertension (Greenwich, Conn.) Vol. 25; no. 11; pp. 1019 - 1026
• Main Authors: liu, mei, Zhao, Zhirong, Lu, Kening, Luo, Qiang, Zhao, Tianjun, Wang, Han
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.11.2023; John Wiley and Sons Inc; Wiley
• Subjects: Age; Anti-inflammatory agents; Antibodies; Arthritis; Blood pressure; Cardiovascular disease; Cholesterol; Creatinine; Cross-Sectional Studies; dermatomyositis; Dermatomyositis - complications; Dermatomyositis - epidemiology; Diabetes; Glucose; Health risks; High density lipoprotein; Humans; Hypertension; Hypertension - complications; Hypertension - epidemiology; Laboratories; Lipoproteins; Nonsteroidal anti-inflammatory drugs; Original; Plasma; polymyositis; Polymyositis - complications; Polymyositis - epidemiology; Reactive oxygen species; Regression analysis; Steroids; Systematic review; Triglycerides; Uric Acid; Variables; polymyositis; dermatomyositis; hypertension; uric acid
• ISSN: 1524-6175; 1751-7176; 1751-7176
• DOI: 10.1111/jch.14730

Serum uric acid (UA), as an antioxidant, has been associated with hypertension in the general population. Hypertension is highly prevalent in patients with polymyositis and dermatomyositis (PM/DM). Owning elevated levels of reactive oxygen species, patients with PM/DM have lower concentrations of UA in comparison with healthy people. We explored a potential association between UA levels and hypertension in PM/DM and evaluated whether this association is independent of hypertension risk factors, PM/DM characteristics and relevant drugs. A total of 472 PM/DM patients were assessed. UA and related laboratory data were measured. Demographic, hypertension‐related factors, PM/DM characteristics and drug use were assessed as potential covariates. Results were analyzed using logistic models to test the independence of the association between UA and hypertension. UA levels were higher in hypertension subjects compared to non‐hypertensive PM/DM patients [284.70 (239.93‐357.38) vs 264.00(222.50‐322.75), p  = .017]. When adjusted for hypertension risk factors, PM/DM characteristics and drugs, the odds of being a hypertensive PM/DM patient per 1 μmol/L UA increase were significantly increased: odds ratio = 1.473 (95% confidence interval:1.063‐2.042, p  = .020). This cross‐sectional study suggests that UA levels are independently associated with hypertension in PM/DM patients.